Inspire Pharma's Inspiring Data

Tags: isph, agn
12 Jan 11:47pm
Posted by ZacksResearch
0 Comments
Read original blog entry

Inspire Pharmaceuticals, Inc. (ISPH) is a specialty pharmaceutical company focused on the development and commercialization of treatments for respiratory and ophthalmologic disorders. Currently, the company has three products on the market and a robust pipeline.

We see strong top line growth from 2008 and beyond. Inspire just reported positive phase III data of Denufosol for CF [cystic fibrosis]. The company has a strong collaborative alliance with Allergan Pharmaceuticals (AGN) for key products that treat dry eyes and allergic conjunctivitis.

The current price is attractive. We maintain our Buy rating on shares of Inspire with a price target of $7.00.

Read the full analyst report on ISPH

Read the full analyst report on AGN




Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all today’s Analyst Blog entries on Zacks.com.

Comments

Back to top

Post comment

Back to top

Post a comment

Please login to post a comment

About

ZacksResearch

Zacks Investment Research is one of the most highly regarded firms in the investment industry. Our firm has long believed that that quantitative models (like the Zacks Rank) can predict stock prices more accurately than individual analysts. However we also recognize that models are most effective when they are employed by analysts who have deep fundamental knowledge of the company and its industry. Consequently Zacks Equity Research combines Zacks quantitative models with the insight provided by an experienced team of 50 analysts to create superior long term stock recommendations. Discover all their timely insight and recommendations daily on Zacks.com.

Recent Entries